Simply as a point of interest as some may not have been aware, the RGNX gene therapy P3 trials partnered with ABBV that reads out later this year is a sub-retinal procedure.
That comes with a vitrectomy as part of the package.
It has the side benefit of cleaning up floaters, of course, along with the associated risks of retinal tears, cataracts and so on.
They enrolled more than 600 in each of the trials.
Market Data 
Markets 
AI
